Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200640217> ?p ?o ?g. }
- W3200640217 endingPage "107" @default.
- W3200640217 startingPage "107" @default.
- W3200640217 abstract "MICA and MICB are tightly regulated stress-induced proteins that trigger the immune system by binding to the activating receptor NKG2D on cytotoxic lymphocytes. MICA and MICB are highly polymorphic molecules with prevalent expression on several types of solid tumors and limited expression in normal/healthy tissues, making them attractive targets for therapeutic intervention.We have generated a series of anti-MICA and MICB cross-reactive antibodies with the unique feature of binding to the most prevalent isoforms of both these molecules.The anti-MICA and MICB antibody MICAB1, a human IgG1 Fc-engineered monoclonal antibody (mAb), displayed potent antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) of MICA/B-expressing tumor cells in vitro. However, it showed insufficient efficiency against solid tumors in vivo, which prompted the development of antibody-drug conjugates (ADC). Indeed, optimal tumor control was achieved with MICAB1-ADC format in several solid tumor models, including patient-derived xenografts (PDX) and carcinogen-induced tumors in immunocompetent MICAgen transgenic mice.These data indicate that MICA and MICB are promising targets for cytotoxic immunotherapy." @default.
- W3200640217 created "2021-09-27" @default.
- W3200640217 creator A5000205943 @default.
- W3200640217 creator A5003282010 @default.
- W3200640217 creator A5003813075 @default.
- W3200640217 creator A5006659812 @default.
- W3200640217 creator A5012054683 @default.
- W3200640217 creator A5017369958 @default.
- W3200640217 creator A5018349448 @default.
- W3200640217 creator A5019457274 @default.
- W3200640217 creator A5021889312 @default.
- W3200640217 creator A5024652775 @default.
- W3200640217 creator A5024776506 @default.
- W3200640217 creator A5025722773 @default.
- W3200640217 creator A5036634814 @default.
- W3200640217 creator A5037368843 @default.
- W3200640217 creator A5039329858 @default.
- W3200640217 creator A5041061728 @default.
- W3200640217 creator A5042587344 @default.
- W3200640217 creator A5051292571 @default.
- W3200640217 creator A5055595028 @default.
- W3200640217 creator A5061502185 @default.
- W3200640217 creator A5064976704 @default.
- W3200640217 creator A5065219709 @default.
- W3200640217 creator A5069095465 @default.
- W3200640217 creator A5070619706 @default.
- W3200640217 creator A5078486100 @default.
- W3200640217 creator A5079765964 @default.
- W3200640217 creator A5081121575 @default.
- W3200640217 creator A5090256483 @default.
- W3200640217 creator A5090853676 @default.
- W3200640217 date "2021-10-27" @default.
- W3200640217 modified "2023-10-17" @default.
- W3200640217 title "Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control" @default.
- W3200640217 cites W1532737852 @default.
- W3200640217 cites W1642437933 @default.
- W3200640217 cites W1982780404 @default.
- W3200640217 cites W1989171408 @default.
- W3200640217 cites W1992376269 @default.
- W3200640217 cites W1993786192 @default.
- W3200640217 cites W1997893106 @default.
- W3200640217 cites W1999341606 @default.
- W3200640217 cites W2000493585 @default.
- W3200640217 cites W2002768361 @default.
- W3200640217 cites W2007826451 @default.
- W3200640217 cites W2014349052 @default.
- W3200640217 cites W2026859850 @default.
- W3200640217 cites W2030249962 @default.
- W3200640217 cites W2056204715 @default.
- W3200640217 cites W2058550324 @default.
- W3200640217 cites W2060387930 @default.
- W3200640217 cites W2079404950 @default.
- W3200640217 cites W2084292672 @default.
- W3200640217 cites W2117269475 @default.
- W3200640217 cites W2126078977 @default.
- W3200640217 cites W2133122919 @default.
- W3200640217 cites W2137763083 @default.
- W3200640217 cites W2143428933 @default.
- W3200640217 cites W2143561528 @default.
- W3200640217 cites W2146783950 @default.
- W3200640217 cites W2148334703 @default.
- W3200640217 cites W2166970460 @default.
- W3200640217 cites W2170069789 @default.
- W3200640217 cites W2403458189 @default.
- W3200640217 cites W2600723487 @default.
- W3200640217 cites W2746257012 @default.
- W3200640217 cites W2791483720 @default.
- W3200640217 cites W2795256310 @default.
- W3200640217 cites W2901317265 @default.
- W3200640217 cites W2903686952 @default.
- W3200640217 cites W2915483287 @default.
- W3200640217 cites W2935912602 @default.
- W3200640217 cites W2958014316 @default.
- W3200640217 cites W2958762925 @default.
- W3200640217 cites W2969718051 @default.
- W3200640217 cites W2986702822 @default.
- W3200640217 cites W3013670789 @default.
- W3200640217 cites W3013978609 @default.
- W3200640217 cites W3017776910 @default.
- W3200640217 cites W3032956486 @default.
- W3200640217 cites W3034835401 @default.
- W3200640217 cites W3047746446 @default.
- W3200640217 cites W838749923 @default.
- W3200640217 cites W90172326 @default.
- W3200640217 doi "https://doi.org/10.12688/openreseurope.13314.2" @default.
- W3200640217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35967081" @default.
- W3200640217 hasPublicationYear "2021" @default.
- W3200640217 type Work @default.
- W3200640217 sameAs 3200640217 @default.
- W3200640217 citedByCount "1" @default.
- W3200640217 countsByYear W32006402172023 @default.
- W3200640217 crossrefType "journal-article" @default.
- W3200640217 hasAuthorship W3200640217A5000205943 @default.
- W3200640217 hasAuthorship W3200640217A5003282010 @default.
- W3200640217 hasAuthorship W3200640217A5003813075 @default.
- W3200640217 hasAuthorship W3200640217A5006659812 @default.
- W3200640217 hasAuthorship W3200640217A5012054683 @default.
- W3200640217 hasAuthorship W3200640217A5017369958 @default.